MTOR and poorly differentiated thyroid gland carcinoma: Deep response to a combination of mTOR inhibitor temsirolimus and dual immunotherapy of nivolumab/ipilimumab in poorly differentiated thyroid carcinoma with <i>PTEN</i> mutation: a case report and literature review.